Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Complete Mesogastric Excision Compared with Conventional D2 in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer: Safety and Efficacy Analysis of a Randomized Clinical Trial
71 Pages Posted: 26 Jun 2020
More...Abstract
IMPORTANCE: Implementation of complete mesogastric excision in gastric cancer surgery, named D2 lymphadenectomy plus complete mesogastric excision (D2+CME), was proposed as a novel optimal procedure. However, the safety and efficacy of D2+CME remain uncertain.
OBJECTIVE: To compare short-term outcomes of patients with advanced gastric cancer after D2+CME or conventional D2 in laparoscopic gastrectomy.
DESIGN, SETTING, AND PARTICIPANTS: Between September 2014 and June 2018, a prospective, randomized, parallel-controlled trial was conducted at a tertiary referral teaching hospital (Department of Gastrointestinal Surgery, Tongji Hospital, Wuhan, China). Patients between 18 to 75 years of age with locally advanced gastric cancer (cT2-4a,N0/+,M0) were enrolled and randomized. The surgical outcomes and postoperative data were compared between the groups in a modified intention-to-treat (mITT) analysis.
INTERVENTIONS: Participants were randomized to undergo either D2+CME (n=243) or conventional D2 (n=243) procedure.
MAIN OUTCOMES AND MEASURES: The primary end point was 3-year disease-free survival rate. The current study presented surgical outcomes, 30-day postoperative morbidity and mortality, postoperative recovery indexes.
RESULTS: In total, 486 participants were randomized in this study. Among them, 243 were assigned to D2 group and 243 were assigned to D2+CME group. After postsurgical exclusions, 338 patients were included in the modified intention-to-treat analysis, which comprised 169 patients (111 men and 58 women; mean [SD] age, 54•5 [9•3] years) in the D2 group and 169 patients (102 men and 67 women; mean [SD] age, 54•8 [9•5] years) in the D2+CME group. Patients in D2+CME group showed less intraoperative blood loss (median [IQR]; 15•0 [23•0] ml in D2+CME vs. 37•0 [33•5] ml in D2, p<0•0001), more lymph node harvesting (median [IQR]; 34 [16] lymph nodes in D2+CME vs. 27 [13] lymph nodes in D2, p<0•0001) and earlier postoperative flatus (p=0•009) than those in D2 group. The overall postoperative complication rate was comparable between the two groups (20•1% in D2+CME vs. 16•0% in D2, p=0•322), however, patients in D2+CME group were less likely to have severe complications (Clavien-Dindo Classification grade ≥IIIa: 4 in D2+CME vs. 9 in D2, p=0•041). No mortality occurred in either group.
CONCLUSION: D2+CME is associated with advantages in intraoperative blood loss, lymph nodes harvest and postoperative flatus duration, and could provide better surgical safety than conventional D2 in laparoscopic gastrectomy.
TRIAL REGISTRATION: ClinicalTrials.gov; NCT01978444
FUNDING STATEMENT: This work was supported by grants from the National Natural Science Foundation of China, Grant numbers: 81171927, 81372324, 81874185.
DECLARATION OF INTERESTS: The authors have no conflicts of interest to disclose.
ETHICS APPROVAL STATEMENT: The study was approved by the Tongji Hospital Ethics Committee (TJ-C20130811). All patients signed an informed consent document to participate in this study.
Keywords: Complete mesogastric excision; D2; advanced gastric cancer; laparoscopic gastrectomy; randomized clinical trial
Suggested Citation: Suggested Citation